Supplementary Material for:

Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model

Ishita Das, Joo-Min Park, Jung H. Shin, Soo Kyeong Jeon, Hernan Lorenzi, David J. Linden, Paul F. Worley, Roger H. Reeves*

*Corresponding author. E-mail: rreeves@jhmi.edu

Published 4 September 2013, Sci. Transl. Med. 5, 201ra120 (2013)
DOI: 10.1126/scitranslmed.3005983

This PDF file includes:

• Notes
• Fig. S1. SAG had mitogenic activity in primary GCP cultures.
• Fig. S2. Dentate gyrus is not affected by SAG treatment.
• Fig. S3. SAG treatment does not affect open-field performance.
• Fig. S4. SAG treatment does not improve Y maze performance in Ts65Dn mice.
• Fig. S5. SAG treatment normalizes search strategies of Ts65Dn mice in the MWM.
• Table S1. Cerebellar morphological measurements.
• Table S2. Dentate gyrus granule cell number at P6 (hematoxylin-stained).
• Table S3. BrdU-positive cells in the DG at P6.
• Table S4. Electrophysiological measurements from cerebellar Purkinje cells.
• Table S5. Open-field activity.
• Table S6. Total number of entries and percent alternation in Y maze.
• Table S7. Latency in the MWM visible platform test (seconds).
• Table S8. Latency in the MWM hidden platform test (seconds).
• Table S9. Time spent in the correct quadrant in the MWM probe test (seconds).
• Table S10. Strategy scores of animals in hidden platform test, by day and trial number.
• Table S11. Relationship between FV amplitude and fEPSP slope.
• Table S12. Paired pulse ratio.
• Table S13. TBS-LTP enhanced by SAG in slices from Ts65Dn mice.
• Table S14. Current-voltage relationship.
• Table S15. NMDA/AMPA ratio.

[Download PDF]